Celltrion Pharm (Korea) Performance
| 068760 Stock | KRW 59,800 1,300 2.13% |
The firm shows a Beta (market volatility) of -0.63, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Celltrion Pharm are expected to decrease at a much lower rate. During the bear market, Celltrion Pharm is likely to outperform the market. At this point, Celltrion Pharm has a negative expected return of -0.22%. Please make sure to confirm Celltrion Pharm's coefficient of variation, jensen alpha, treynor ratio, as well as the relationship between the standard deviation and total risk alpha , to decide if Celltrion Pharm performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Celltrion Pharm has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Total Cashflows From Investing Activities | -16.3 B |
Celltrion |
Celltrion Pharm Relative Risk vs. Return Landscape
If you would invest 7,070,000 in Celltrion Pharm on September 22, 2024 and sell it today you would lose (1,090,000) from holding Celltrion Pharm or give up 15.42% of portfolio value over 90 days. Celltrion Pharm is generating negative expected returns and assumes 2.9852% volatility on return distribution over the 90 days horizon. Simply put, 26% of stocks are less volatile than Celltrion, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Celltrion Pharm Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Celltrion Pharm's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Celltrion Pharm, and traders can use it to determine the average amount a Celltrion Pharm's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0744
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 068760 |
Estimated Market Risk
| 2.99 actual daily | 26 74% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.07 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Celltrion Pharm is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Celltrion Pharm by adding Celltrion Pharm to a well-diversified portfolio.
Celltrion Pharm Fundamentals Growth
Celltrion Stock prices reflect investors' perceptions of the future prospects and financial health of Celltrion Pharm, and Celltrion Pharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Celltrion Stock performance.
| Return On Equity | 0.0891 | |||
| Return On Asset | 0.0341 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.11 % | |||
| Current Valuation | 5.87 T | |||
| Shares Outstanding | 34.05 M | |||
| Price To Earning | 62.82 X | |||
| Price To Sales | 8.22 X | |||
| Revenue | 398.74 B | |||
| EBITDA | 42.8 B | |||
| Cash And Equivalents | 80.19 B | |||
| Cash Per Share | 815.33 X | |||
| Total Debt | 39.4 B | |||
| Debt To Equity | 0.64 % | |||
| Book Value Per Share | 10,914 X | |||
| Cash Flow From Operations | 93.15 B | |||
| Total Asset | 637.88 B | |||
| Retained Earnings | 30.6 B | |||
| Current Asset | 144.21 B | |||
| Current Liabilities | 85.27 B | |||
About Celltrion Pharm Performance
By analyzing Celltrion Pharm's fundamental ratios, stakeholders can gain valuable insights into Celltrion Pharm's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Celltrion Pharm has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Celltrion Pharm has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea. Celltrionph is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Celltrion Pharm performance evaluation
Checking the ongoing alerts about Celltrion Pharm for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Celltrion Pharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Celltrion Pharm generated a negative expected return over the last 90 days | |
| About 58.0% of the company shares are owned by insiders or employees |
- Analyzing Celltrion Pharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Celltrion Pharm's stock is overvalued or undervalued compared to its peers.
- Examining Celltrion Pharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Celltrion Pharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Celltrion Pharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Celltrion Pharm's stock. These opinions can provide insight into Celltrion Pharm's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Celltrion Stock analysis
When running Celltrion Pharm's price analysis, check to measure Celltrion Pharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celltrion Pharm is operating at the current time. Most of Celltrion Pharm's value examination focuses on studying past and present price action to predict the probability of Celltrion Pharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celltrion Pharm's price. Additionally, you may evaluate how the addition of Celltrion Pharm to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |